{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:16:07Z","timestamp":1793103367881,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejpn.2022.04.006","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T01:59:28Z","timestamp":1651283968000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"special_numbering":"C","title":["Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7527-8435","authenticated-orcid":false,"given":"Judit","family":"Erdos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2022.04.006_bib1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ejpn.2022.04.006_bib2","series-title":"Dossier zur Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V","article-title":"Nusinersen (Spinraza\u00ae) modul 3 A 5q-assoziierte spinale muskelatrophie (SMA)","author":"Gemeinsamer Bundesausschuss (G-BA)","year":"2020"},{"key":"10.1016\/j.ejpn.2022.04.006_bib3","series-title":"Spinraza (Nusinersen)","year":"2017"},{"key":"10.1016\/j.ejpn.2022.04.006_bib64","series-title":"Zolgensma (onasemnogene abeparvovec)","author":"European Medicines Agency (EMA)","year":"2020"},{"key":"10.1016\/j.ejpn.2022.04.006_bib65","series-title":"Zolgensma","author":"Food and Drug Administration (FDA)","year":"2019"},{"key":"10.1016\/j.ejpn.2022.04.006_bib6","series-title":"Evrysdi (Risdiplam)","year":"2021"},{"key":"10.1016\/j.ejpn.2022.04.006_bib7","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejpn.2022.04.006_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejpn.2022.04.006_bib9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls","volume":"385","author":"Darras","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejpn.2022.04.006_bib10","first-page":"166","article-title":"Firefish part 2: efficacy and safety of risdiplam (rg7916) in infants with type 1 spinal muscular atrophy (SMA)","volume":"27","author":"Servais","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejpn.2022.04.006_bib11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejpn.2022.04.006_bib12","first-page":"S126","article-title":"Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): long-term follow-up from the onasemnogene abeparvovec phase 1\/2a clinical trial","volume":"86","author":"Mendell","year":"2019","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.ejpn.2022.04.006_bib13","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-Year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejpn.2022.04.006_bib14","series-title":"Quality Appraisal of Case Series Studies Checklist","year":"2014"},{"key":"10.1016\/j.ejpn.2022.04.006_bib19","series-title":"Briefing Document to the Clinical Trial Readiness in Spinal Muscular Atrophy (SMA) SMA Europe","year":"2016"},{"key":"10.1016\/j.ejpn.2022.04.006_bib20","series-title":"209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7\u20139 November 2014","first-page":"593","volume":"vol. 25","author":"Finkel","year":"2015"},{"key":"10.1016\/j.ejpn.2022.04.006_bib21","series-title":"Best Practices for Physical Therapists & Clinical Evaluators in Spinal Muscular Atrophy (SMA). Recommendations to Support the Effective Conduct of Clinical Trials in SMA","author":"Krosschell","year":"2019"},{"key":"10.1016\/j.ejpn.2022.04.006_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/2329048X211008725","article-title":"Spinal muscular atrophy: the use of functional motor scales in the era of disease-modifying treatment","volume":"8","author":"Pierzchlewicz","year":"2021","journal-title":"Child Neurol. Open"},{"key":"10.1016\/j.ejpn.2022.04.006_bib23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13023-020-01414-8","article-title":"Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study","volume":"15","author":"Audic","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejpn.2022.04.006_bib24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/ppul.25142","article-title":"Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen","volume":"56","author":"G\u00f3mez-Garc\u00eda de la Banda","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.ejpn.2022.04.006_bib25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.ejpn.2022.04.006_bib26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/JND-190403","article-title":"AVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort","volume":"6","author":"Al-Zaidy","year":"2019","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ejpn.2022.04.006_bib27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","article-title":"Impact of age and motor function in a phase 1\/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy","volume":"98","author":"Lowes","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ejpn.2022.04.006_bib28","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2022.04.006_bib29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/mus.26633","article-title":"Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy","volume":"60","author":"Montes","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejpn.2022.04.006_bib35","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mus.27187","article-title":"Safety and efficacy of nusinersen in spinal muscular atrophy: the EMBRACE study","volume":"63","author":"Acsadi","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejpn.2022.04.006_bib34","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/dmcn.14412","article-title":"Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen","volume":"62","author":"Aragon-Gawinska","year":"2020","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ejpn.2022.04.006_bib32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ppul.25140","article-title":"Nusinersen for spinal muscular atrophy type 1: real-world respiratory experience","volume":"56","author":"Lavie","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.ejpn.2022.04.006_bib33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/JND-200533","article-title":"Clinical outcomes in patients with spinal muscular atrophy type 1 treated with nusinersen","volume":"8","author":"de Holanda Mendon\u00e7a","year":"2021","journal-title":"J.\u00a0Neuromuscul. Dis."},{"issue":"3","key":"10.1016\/j.ejpn.2022.04.006_bib63","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5603\/PJNNS.a2021.0020","article-title":"Nusinersen treatment of spinal muscular atrophy type 1\u2014 results of expanded access programme in Poland","volume":"55","author":"Modrzejewska1","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.ejpn.2022.04.006_bib30","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ana.25533","article-title":"Nusinersen in type 1 spinal muscular atrophy: twelve-month real-world data","volume":"86","author":"Pane","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejpn.2022.04.006_bib36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/thoraxjnl-2020-216564","article-title":"Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1-3","volume":"77","author":"Chacko","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.ejpn.2022.04.006_bib37","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/jnnp-2020-324254","article-title":"Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen","volume":"92","author":"Kariyawasam","year":"2020","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejpn.2022.04.006_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2020.11.004","article-title":"Children and young adults with spinal muscular atrophy treated with nusinersen","volume":"30","author":"Osredkar","year":"2021","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.ejpn.2022.04.006_bib39","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/mus.26769","article-title":"Nusinersen for older patients with spinal muscular atrophy: a real-world clinical setting experience","volume":"61","author":"Veerapandiyan","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejpn.2022.04.006_bib40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejpn.2022.04.006_bib41","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","article-title":"Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3","volume":"91","author":"Maggi","year":"2020","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.ejpn.2022.04.006_bib42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3233\/JND-200551","article-title":"Real-world data from nusinersen treatment for patients with later-onset spinal muscular atrophy: a single center experience","volume":"8","author":"Mendonca","year":"2021","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ejpn.2022.04.006_bib43","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1212\/WNL.0000000000009914","article-title":"Nusinersen in adult patients with spinal muscular atrophy: observations from a single center","volume":"95","author":"Moshe-Lilie","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2022.04.006_bib44","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3233\/JND-190453","article-title":"Prospective cohort study of nusinersen treatment in adults with spinal muscular atrophy","volume":"7","author":"Yeo","year":"2020","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ejpn.2022.04.006_bib46","first-page":"950","article-title":"An observational cohort study on impact, dimensions and outcome of perceived fatigue in adult 5q-spinal muscular atrophy patients receiving nusinersen treatment","volume":"268","author":"Binz","year":"2020","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.ejpn.2022.04.006_bib45","first-page":"923","article-title":"Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4","volume":"268","author":"De Wel","year":"2020","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.ejpn.2022.04.006_bib47","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/mus.27034","article-title":"Combination molecular therapies for type 1 spinal muscular atrophy","volume":"62","author":"Harada","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejpn.2022.04.006_bib48","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ppul.25135","article-title":"The respiratory impact of novel therapies for spinal muscular atrophy","volume":"56","author":"Paul","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.ejpn.2022.04.006_bib49","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2022.04.006_bib50","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul. Disord. : NMD"},{"key":"10.1016\/j.ejpn.2022.04.006_bib51","article-title":"Nusinersen treatment of spinal muscular atrophy - a systematic review","volume":"67","author":"Albrechtsen","year":"2020","journal-title":"Dan. Med. J."},{"key":"10.1016\/j.ejpn.2022.04.006_bib52","article-title":"Drug treatment for spinal muscular atrophy type I","volume":"12","author":"Wadman","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejpn.2022.04.006_bib53","article-title":"Drug treatment for spinal muscular atrophy types II and III","volume":"1","author":"Wadman","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejpn.2022.04.006_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066844","article-title":"For the reporting bias group. Systematic review of the empirical evidence of study publication bias and outcome reporting bias \u2014 an updated review","volume":"8","author":"Dwan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpn.2022.04.006_bib55","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2352-4642(21)00100-0","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study","volume":"5","author":"Finkel","year":"2021","journal-title":"Lancet Child Adolesc. Health"},{"key":"10.1016\/j.ejpn.2022.04.006_bib56","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejpn.2022.04.006_bib57","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejpn.2022.04.006_bib58","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/acn3.51276","article-title":"Type I SMA \"new natural history\": long-term data in nusinersen-treated patients","volume":"8","author":"Pane","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ejpn.2022.04.006_bib59","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.nmd.2020.12.006","article-title":"Nusinersen treatment of older children and adults with spinal muscular atrophy","volume":"31","author":"Konersman","year":"2021","journal-title":"Neuromuscul. Disord. : NMD"}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379822000629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379822000629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:38:42Z","timestamp":1761071922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379822000629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":55,"alternative-id":["S1090379822000629"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2022.04.006","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2022.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Austrian Institute for Health Technology Assessment. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}